DR-01 is under clinical development by Dren Bio and currently in Phase II for Leukemia. According to GlobalData, Phase II drugs for Leukemia have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DR-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DR-01 is under development for the treatment of large granular lymphocytic leukemia or cytotoxic lymphomas and autoimmune disorders. The drug candidate is developed based on antibody-based technology platform.
Dren Bio overview
Dren Bio is a biotechnology company that develops protein engineering technologies to expend diseased cells, protein aggregates and agents. It is investigating DR-01 program to kill cells involved in leukemia, lymphomas and autoimmune diseases by using antibody-mediated killing. The company is also evaluating DR-02, an antibody-based platform to develop drugs targeting solid tumors, hematologic neoplasms, infectious diseases and protein aggregate diseases. It was funded by SR One Capital Management LP, Taiho Ventures LLC, BVF Partners LP, Alexandria Venture Investments and other companies. Dren Bio is headquartered in Redwood City, California, the US.
For a complete picture of DR-01’s drug-specific PTSR and LoA scores, buy the report here.